- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06368063
The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Study on the Efficacy and Safety of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Zheng Wang, PhD
- Phone Number: +8615902993665
- Email: zheng.wang11@mail.xjtu.edu.cn
Study Contact Backup
- Name: Liang Han, PhD
- Phone Number: +8613379181359
- Email: hanliangxjtu@163.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age range from 18 to 80 years old, regardless of gender;
- Pancreatic cancer was diagnosed by histopathology after radical surgery within 12 weeks before enrollment;
- Did not receive neoadjuvant therapy before surgery and did not receive any adjuvant therapy after surgery;
- ECOG score 0-3 points;
- Those who choose to use standard chemotherapy independently based on their own situation, or choose Huaier granules for subsequent treatment, voluntarily participate in and cooperate with various research work, including but not limited to cooperating with treatment and follow-up, cooperating with researchers for data collection, and not actively taking other treatments.
- The subjects voluntarily signed a written informed consent form before participating in this study.
Exclusion Criteria:
- Known to be allergic to the components of Huaier granules or to avoid or use Huai er granules with caution (Huaier group);
- Difficulties in taking oral medication due to active gastrointestinal bleeding, perforation, gastric paralysis, etc;
- Suffering from serious mental illness or other reasons that the researcher deems unsuitable to participate in this study.
- History of merging with other malignant tumors;
- Patients with concomitant myocardial infarction, cerebral infarction, and other thromboembolic diseases requiring surgical treatment;
- Concomitant severe infection;
- Child Pugh C-grade liver function, renal function 2-5 grades (glomerular filtration rate<90ml/min);
- Pregnant or lactating women or those planning to conceive;
- The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect, chemotherapy or physical therapy in the past 4 weeks(including but not limited to compound cantharidin capsules, cinobufotalin capsules, Kangai injection, please refer to the drug instructions for details).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Huaier treatment group
The subjects take Huaier granules orally and start taking them within 15-30 days after surgery until the end of the study, intolerable toxicity occurs, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
|
Huaier Granules: Oral administration, 10g once, 3 times a day, starting from 15-30 days after surgery until the end of the study, intolerable toxicity, withdrawal from the study for any reason, or death, whichever occurs first; Or the researcher determines that the subjects no longer benefit.
Other Names:
|
Active Comparator: Standard chemotherapy group
Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment)
|
Accept treatment with Class 1A chemotherapy drugs recommended by CSCO (choose any one to receive treatment) · Gemcitabine combine with capecitabine Gemcitabine 1000mg/m^2 intravenous infusion for more than 30 minutes, day 1, 8, 15,repeat every 4 weeks for a total of 6 cycles. · mFOLFIRINOX solution Oxaliplatin 85mg/m^2 intravenous infusion for 2 hours, day 1 Ilitacan 150mg/m^2 intravenous infusion for more than 30-90 minutes, day 1 Leucovorin calcium 400mg/m^2 intravenous infusion for 2 hours, day 1 5-FU 2400mg/m^2, continuous intravenous infusion for 46 hours, repeated every 2 weeks, administered until 24 weeks.
Take tegio capsules orally, 80mg/d, day 1-28, repeated every 6 weeks, administered until 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease-free survival
Time Frame: Start of treatment until 2-year follow-up
|
It is defined as the time from the first day after radical resection of pancreatic cancer to recurrence or all-cause death of pancreatic cancer.
|
Start of treatment until 2-year follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival
Time Frame: Start of treatment until 2-year follow-up
|
It is defined as the time between the start date of enrollment and the recorded date of all-cause death.
For subjects who were lost to follow-up before death, the last follow-up time is usually calculated as the time of death.
|
Start of treatment until 2-year follow-up
|
Progression-free survival
Time Frame: Start of treatment until 2-year follow-up
|
It is defined as the time between the start date of enrollment and the date of imaging progression or all-cause death evaluated by the investigator.
|
Start of treatment until 2-year follow-up
|
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
Time Frame: Start of treatment until 2-year follow-up
|
The definitions and severity grading of AE and SAE refer to the corresponding descriptions in the definition and evaluation section of AE.
The incidence rate is defined as the proportion of patients with AE and SAE to the corresponding total population.
|
Start of treatment until 2-year follow-up
|
The incidence and severity of ADR, severe adverse reactions (SADR), suspicious and unexpected severe adverse reactions (SUSAR)
Time Frame: Start of treatment until 2-year follow-up
|
The definitions and severity grading of ADR, severe ADR, and SUSAR refer to the corresponding descriptions in the definition and evaluation section of AE.
The incidence rate is defined as the proportion of patients with ADR, severe ADR, and SUSAR to the corresponding total population.
|
Start of treatment until 2-year follow-up
|
Collaborators and Investigators
Investigators
- Principal Investigator: Zheng Wang, PhD, First Affiliated Hospital Xi'an Jiaotong University
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HE-202301
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer Resectable
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsKorea, Republic of, United States, Japan
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
-
Kimberly Perez, MDNovartisTerminatedPancreatic Cancer | Pancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Borderline Resectable Pancreatic AdenocarcinomaUnited States
-
National Cancer Institute (NCI)RecruitingPancreatic Acinar Cell Carcinoma | Pancreatic Adenosquamous Carcinoma | Pancreatic Squamous Cell Carcinoma | Resectable Pancreatic Acinar Cell Carcinoma | Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenosquamous Carcinoma | Resectable Pancreatic CarcinomaUnited States
-
Gangnam Severance HospitalCompletedResectable Pancreatic AdenocarcinomaKorea, Republic of
-
Memorial Sloan Kettering Cancer CenterRecruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Ductal Adenocarcinoma | Locally Advanced Pancreatic Ductal AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterRecruitingBorderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic AdenocarcinomaUnited States
-
Wakayama Medical UniversityRecruitingResectable Pancreatic Body/Tail CarcinomaJapan
-
Lawson Health Research InstituteLondon Health Sciences FoundationNot yet recruitingBorderline Resectable Pancreatic Adenocarcinoma | Resectable Pancreatic Adenocarcinoma
Clinical Trials on Huaier granule
-
Sixth Affiliated Hospital, Sun Yat-sen UniversityQidong Gaitianli Medicines Co., LtdUnknownColorectal CancerChina
-
Tongji HospitalUnknown
-
Shandong UniversityRecruitingTriple Negative Breast CancerChina
-
Ruijin HospitalNot yet recruitingFallopian Tube Cancer | Peritoneal Cancer | Primary Ovarian Cancer
-
Qidong Gaitianli Medicines Co., LtdTerminatedNon-small Cell Lung CancerChina
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...RecruitingEarly-stage Breast CancerChina
-
Qidong Gaitianli Medicines Co., LtdHuazhong University of Science and TechnologyCompleted
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...RecruitingTriple-negative Breast Cancer | Carcinoma Breast | Invasive Ductal Carcinoma, BreastChina
-
Fudan UniversityHuazhong University of Science and Technology; LinkDoc Technology (Beijing)...Not yet recruitingBreast Cancer Stage IVChina
-
Qidong Gaitianli Medicines Co., LtdHuazhong University of Science and TechnologyTerminated